Sepsis and severe malaria together contribute to an estimated 13 million deaths annually, a great burden of which is in low-income countries. Optimal fluid management is critical yet remains one of the most challenging clinical care elements as volume overload precipitates pulmonary edema and volume restriction may exacerbate acute kidney injury. These complications of sepsis and severe malaria significantly increase mortality, particularly in resource-limited settings lacking mechanical ventilation and renal replacement therapy. Point-of-care ultrasound and passive leg raise testing are two easily implementable, safe and non-invasive clinical bedside fluid assessment tools that could be applied towards developing a fluid management algorithm in low resource settings. Similarly, simple tissue perfusion measures can facilitate understanding of precise indications or contraindication to fluid and vasopressor therapy.
However, the performance of these tools has yet to be confirmed in these settings. Accurate assessment of pulmonary tolerance and fluid responsive patients could aid to tailor vasopressor and fluid therapy to the patient condition and disease phase, thus preventing or detecting iatrogenic pulmonary edema and other pulmonary complications. As there is currently limited evidence supporting fluid management recommendations for severe malaria and sepsis in low-resource settings, the potential application of these management tools could optimize supportive therapy and improve outcomes in these populations.
The main activity proposed is a prospective, observational study of patients with sepsis and severe malaria to describe the relationship between fluid therapy and vasopressor therapy against measures of tissue perfusion and pulmonary congestion in adult patients with severe malaria or severe sepsis. In addition, the study will assess the performance of simple bedside clinical tools assessing fluid responsiveness, pulmonary congestion and peripheral tissue perfusion.
The data from this observational study will facilitate the preparation of a follow-up study to test a clinical algorithm to guide individualized fluid and vasopressor administration.
Condition or disease | Intervention/treatment |
---|---|
Severe Sepsis Malaria | Procedure: Lung Ultrasound examination Procedure: Compression ultrasonography (CUS) Procedure: Echocardiography Procedure: Inferior Vena Cava ultrasound Procedure: Passive leg raising test (PLR) Procedure: Orthogonal polarization spectral imaging (OPS) Procedure: Urine collection (Foley catheter) Procedure: Venous blood samplings Procedure: Electrocardiogram Procedure: GlycoCheck |
This will be a single center, prospective, longitudinal, observational study of patients with sepsis or severe malaria. It is planned that this initial observational study will inform a follow-up intervention study, based on the observational study findings (Lung Ultrasound and Passive Leg Raising- guided Vasopressors and Fluid Management in Patients with Sepsis and Severe Malaria). The follow-up study will propose testing of a clinical algorithm to individualize titration of vasopressors, diuretics and fluids based on the simple tools evaluated during the observational study.
The expected duration of study patient participation is 30 days. Patients will be assessed every 6 hours until fever clearance, parasite clearance (in malaria patients) and GCS normalization (score of 15) on two consecutive assessments. Thereafter, patients will be assessed daily until discharge or death with one follow-up visit at 14 days and a follow-up call at day 30. The prospective, observational recruitment phase of the study is expected to last 15 months.
Study Type : | Observational |
Actual Enrollment : | 103 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Perfusion and Lung Congestion Evaluation Related to Fluids and Vasopressors in Sepsis and Malaria. (PERFuSE): an Observational Study |
Actual Study Start Date : | June 4, 2018 |
Actual Primary Completion Date : | August 29, 2019 |
Actual Study Completion Date : | September 26, 2019 |
Group/Cohort | Intervention/treatment |
---|---|
Sepsis |
Procedure: Lung Ultrasound examination
Use of lung ultrasound to detect pulmonary complications
Procedure: Compression ultrasonography (CUS) CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
Procedure: Echocardiography Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
Procedure: Inferior Vena Cava ultrasound Measurement of the inferior vena cava diameter
Procedure: Passive leg raising test (PLR) Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
Procedure: Orthogonal polarization spectral imaging (OPS) Measurement of capillary flow in the rectal microcirculation
Procedure: Urine collection (Foley catheter) For urinalysis, biochemistry, urine microscopy, pH, and culture.
Procedure: Venous blood samplings for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
Procedure: Electrocardiogram all patients will have an ECG performed on enrolment as a non-invasive investigation
Procedure: GlycoCheck GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
|
Severe malaria |
Procedure: Lung Ultrasound examination
Use of lung ultrasound to detect pulmonary complications
Procedure: Compression ultrasonography (CUS) CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
Procedure: Echocardiography Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
Procedure: Inferior Vena Cava ultrasound Measurement of the inferior vena cava diameter
Procedure: Passive leg raising test (PLR) Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
Procedure: Orthogonal polarization spectral imaging (OPS) Measurement of capillary flow in the rectal microcirculation
Procedure: Urine collection (Foley catheter) For urinalysis, biochemistry, urine microscopy, pH, and culture.
Procedure: Venous blood samplings for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
Procedure: Electrocardiogram all patients will have an ECG performed on enrolment as a non-invasive investigation
Procedure: GlycoCheck GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
|
Uncomplicated malaria |
Procedure: Lung Ultrasound examination
Use of lung ultrasound to detect pulmonary complications
Procedure: Compression ultrasonography (CUS) CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
Procedure: Echocardiography Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
Procedure: Inferior Vena Cava ultrasound Measurement of the inferior vena cava diameter
Procedure: Passive leg raising test (PLR) Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
Procedure: Orthogonal polarization spectral imaging (OPS) Measurement of capillary flow in the rectal microcirculation
Procedure: Urine collection (Foley catheter) For urinalysis, biochemistry, urine microscopy, pH, and culture.
Procedure: Venous blood samplings for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
Procedure: Electrocardiogram all patients will have an ECG performed on enrolment as a non-invasive investigation
Procedure: GlycoCheck GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
|
Hematocrit and peripheral blood parasitemia in thin and thick films will be assessed at T=0 (enrolment) then 6-hourly until parasite clearance (two consecutive negative thick smears per 500 white blood cells). Plasma creatinine will be measured 24-hourly for 72 hours, at discharge and day 14. Venous blood gas and lactate will be assessed 6-hourly until lactate <2 mmol/L.
Arterial blood gas will be collected at T0 and after 24 hours if the subject is in respiratory distress, defined as respiratory rate > 30 breaths per minute and SpO2 <92% on room air. More frequent hematological and biochemical measurements may be done if clinically indicated at the discretion of the treating clinician. Plasma cell-free hemoglobin (CFH) will be analyzed at hour 0, 6, 24, 48, 72 and day 7 in the severe malaria group and only hour 0 in sepsis and uncomplicated malaria groups. Blood cultures and additional microbiology assays will be drawn at enrolment and performed locally.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
I. Sepsis criteria:
The sepsis criteria include the severe sepsis and septic shock categories according to 2012 Surviving Sepsis Campaign guidelines. Due to a possible delay in obtaining all the enrolment sequential organ failure assessment (SOFA) score variables necessary to fulfil the criteria for the latest 2016 sepsis definition, the 2012 Surviving Sepsis Campaign criteria and the quick SOFA tool will be used for inclusion. However, after study completion, when all admission SOFA scores will be available, all patients will be re-scored according to the Sepsis 3 definition.
Inclusion criteria for sepsis:
Systolic blood pressure ≤ 100 mmHg, or receiving vasopressor (epinephrine, norepinephrine, dopamine)
PLUS one or more of the following:
A. Respiratory rate ≥22 breaths per minute or under oxygen therapy or mechanical ventilation B. Altered mental status (Glasgow Coma Scale ≤ 14)
Note: Positive blood or urine cultures not required as eligibility criteria due to limited microbiology laboratory availability.
II. Severe malaria criteria Using modified World Health Organization criteria for severe falciparum malaria, as defined previously.
Any P. falciparum or P. vivax parasitaemia in adults, detected by asexual stages on a peripheral blood- slide or a positive RDT in combination with one or more:
i. GCS <11 ii. Hematocrit < 20% with parasite count >100,000/mm3 iii. Jaundice with parasite count >100,000/mm3 iv. Serum creatinine >3 mg/dL (or anuria) v. Hypoglycemia with venous glucose <40 mg/dL vi. Systolic blood pressure <80 mmHg with cool extremities vii. Peripheral asexual stage parasitemia >10 % viii. Peripheral venous lactate >4 mmol/L ix. Peripheral venous bicarbonate <15 mmol/L x. Respiratory distress/pulmonary edema: radiologically confirmed, or oxygen saturation <92% on room air with a respiratory rate >30/min, often with chest indrawing and crepitations on auscultation xi. Spontaneous bleeding xii. Generalized convulsions (≥2 in 24 hours)
III. Uncomplicated malaria criteria (control group)
Exclusion Criteria
The participant may not enter the study if ANY of the following apply:
Bangladesh | |
Chittagong Medical College Hospital | |
Chittagong, Bangladesh |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | May 29, 2018 | ||||
First Posted Date | August 22, 2018 | ||||
Last Update Posted Date | October 1, 2020 | ||||
Actual Study Start Date | June 4, 2018 | ||||
Actual Primary Completion Date | August 29, 2019 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
|
||||
Original Primary Outcome Measures |
|
||||
Change History | |||||
Current Secondary Outcome Measures |
|
||||
Original Secondary Outcome Measures |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Monitoring of Perfusion in Sepsis and Malaria | ||||
Official Title | Perfusion and Lung Congestion Evaluation Related to Fluids and Vasopressors in Sepsis and Malaria. (PERFuSE): an Observational Study | ||||
Brief Summary |
Sepsis and severe malaria together contribute to an estimated 13 million deaths annually, a great burden of which is in low-income countries. Optimal fluid management is critical yet remains one of the most challenging clinical care elements as volume overload precipitates pulmonary edema and volume restriction may exacerbate acute kidney injury. These complications of sepsis and severe malaria significantly increase mortality, particularly in resource-limited settings lacking mechanical ventilation and renal replacement therapy. Point-of-care ultrasound and passive leg raise testing are two easily implementable, safe and non-invasive clinical bedside fluid assessment tools that could be applied towards developing a fluid management algorithm in low resource settings. Similarly, simple tissue perfusion measures can facilitate understanding of precise indications or contraindication to fluid and vasopressor therapy. However, the performance of these tools has yet to be confirmed in these settings. Accurate assessment of pulmonary tolerance and fluid responsive patients could aid to tailor vasopressor and fluid therapy to the patient condition and disease phase, thus preventing or detecting iatrogenic pulmonary edema and other pulmonary complications. As there is currently limited evidence supporting fluid management recommendations for severe malaria and sepsis in low-resource settings, the potential application of these management tools could optimize supportive therapy and improve outcomes in these populations. The main activity proposed is a prospective, observational study of patients with sepsis and severe malaria to describe the relationship between fluid therapy and vasopressor therapy against measures of tissue perfusion and pulmonary congestion in adult patients with severe malaria or severe sepsis. In addition, the study will assess the performance of simple bedside clinical tools assessing fluid responsiveness, pulmonary congestion and peripheral tissue perfusion. The data from this observational study will facilitate the preparation of a follow-up study to test a clinical algorithm to guide individualized fluid and vasopressor administration. |
||||
Detailed Description |
This will be a single center, prospective, longitudinal, observational study of patients with sepsis or severe malaria. It is planned that this initial observational study will inform a follow-up intervention study, based on the observational study findings (Lung Ultrasound and Passive Leg Raising- guided Vasopressors and Fluid Management in Patients with Sepsis and Severe Malaria). The follow-up study will propose testing of a clinical algorithm to individualize titration of vasopressors, diuretics and fluids based on the simple tools evaluated during the observational study. The expected duration of study patient participation is 30 days. Patients will be assessed every 6 hours until fever clearance, parasite clearance (in malaria patients) and GCS normalization (score of 15) on two consecutive assessments. Thereafter, patients will be assessed daily until discharge or death with one follow-up visit at 14 days and a follow-up call at day 30. The prospective, observational recruitment phase of the study is expected to last 15 months. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Case-Control Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Retention: Samples With DNA Description:
Hematocrit and peripheral blood parasitemia in thin and thick films will be assessed at T=0 (enrolment) then 6-hourly until parasite clearance (two consecutive negative thick smears per 500 white blood cells). Plasma creatinine will be measured 24-hourly for 72 hours, at discharge and day 14. Venous blood gas and lactate will be assessed 6-hourly until lactate <2 mmol/L. Arterial blood gas will be collected at T0 and after 24 hours if the subject is in respiratory distress, defined as respiratory rate > 30 breaths per minute and SpO2 <92% on room air. More frequent hematological and biochemical measurements may be done if clinically indicated at the discretion of the treating clinician. Plasma cell-free hemoglobin (CFH) will be analyzed at hour 0, 6, 24, 48, 72 and day 7 in the severe malaria group and only hour 0 in sepsis and uncomplicated malaria groups. Blood cultures and additional microbiology assays will be drawn at enrolment and performed locally. |
||||
Sampling Method | Non-Probability Sample | ||||
Study Population | Male or female subjects, aged ≥12 years hospitalized with malaria or sepsis. | ||||
Condition |
|
||||
Intervention |
|
||||
Study Groups/Cohorts |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Completed | ||||
Actual Enrollment |
103 | ||||
Original Estimated Enrollment |
250 | ||||
Actual Study Completion Date | September 26, 2019 | ||||
Actual Primary Completion Date | August 29, 2019 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria |
Inclusion Criteria: I. Sepsis criteria: The sepsis criteria include the severe sepsis and septic shock categories according to 2012 Surviving Sepsis Campaign guidelines. Due to a possible delay in obtaining all the enrolment sequential organ failure assessment (SOFA) score variables necessary to fulfil the criteria for the latest 2016 sepsis definition, the 2012 Surviving Sepsis Campaign criteria and the quick SOFA tool will be used for inclusion. However, after study completion, when all admission SOFA scores will be available, all patients will be re-scored according to the Sepsis 3 definition. Inclusion criteria for sepsis:
Note: Positive blood or urine cultures not required as eligibility criteria due to limited microbiology laboratory availability. II. Severe malaria criteria Using modified World Health Organization criteria for severe falciparum malaria, as defined previously.
III. Uncomplicated malaria criteria (control group)
Exclusion Criteria The participant may not enter the study if ANY of the following apply:
|
||||
Sex/Gender |
|
||||
Ages | 12 Years and older (Child, Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries | Bangladesh | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT03641534 | ||||
Other Study ID Numbers | MAL18001 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement | Not Provided | ||||
Responsible Party | University of Oxford | ||||
Study Sponsor | University of Oxford | ||||
Collaborators |
|
||||
Investigators | Not Provided | ||||
PRS Account | University of Oxford | ||||
Verification Date | September 2020 |